Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.

Trial Profile

Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Mifepristone (Primary) ; Eribulin
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Corcept Therapeutics
  • Most Recent Events

    • 21 Jul 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
    • 21 Jul 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.
    • 21 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top